Abstract
Objective-To investigate the occurrence ofanti-annexin V autoantibodies in sera of patients with rheumatoid arthritis to assess involvement with the disease and any relation to glucocorticoid treatment. Methods-Anti-annexin V antibodies were measured by an enzyme linked inmunosorbent assay (EuSA) which used the purified hman recombinant protein as antigen.
Results-Concentrations of anti-annexin V autoantibodies, predominantly of the IgG class, were significantly raised in sera from patients with rheumatoid arthritis compared to normal controls. This was not correlated with other indices of disease activity such as erythrocyte sedimentation rate or C reactive protein and was unrelated to glucocorticoid treatment. Conclusions-Extracellular annexin V provides an antigenic stimulus for autoantibody production and its in vivo expression is independent of glucocorticoid control. Such 4 Various annexins appear to be secreted by an exocytotic mechanism from cells in a collagen matrix and may thus play a role in remodelling the extracellular matrix.' Annexins also effectively inhibit types I, II, and III phospholipase A2 by distinct mechanisms. 6 The presence of raised concentrations of autoantibodies to human annexin I, V, and XI proteins (ANX1, ANX5, and ANX1 1) in various autoimmune diseases7" has received attention because of the anti-inflammatory role of these proteins and their apparent inducibility by glucocorticoids used for treatment. '4 In rheumatoid arthritis, anti-ANX1 IgG was normal but IgM was stimulated following glucocorticoid treatment.'5 Anti-ANXl 1 IgG autoantibodies directed at epitopes in the unique N-terminus of this annexin were increased in rheumatoid arthritis and other autoimmune diseases.'6 Anti-ANX5 autoantibodies in systemic lupus erythematosus and pre-eclampsia may increase the risk of thrombosis," ' Figure 2 Anti-annexin V autoantibody levels in Figure 3 Anti-annexin V autoantibody levels in rheumatoid arthritis patients and normal controls. ELiSA rheumatoid arthritis patients grouped according to readings were taken from sera of 49 healthy wlunteers glucocorticoid treatment regimen. Group 1 (n = 17) (empty circles) and 5I patients diagnosed with rheumatoid received no steroid treatment, group 2 (n = 19) 5) . Another recent study also observed a significant elevation of IgG-specific autoantibodies to both ANX5 and ANX6 in a smaller sample group of rheumatoid arthritis patients.'2 The authors noted a similar lack of correlation in antibody levels with disease activity, RF level, or glucocorticoid treatment. However, negative correlations between IgG concentrations and patient age or glucocorticoid dosage were not confirmed by the present study, and may simply be related to the apparent decline of disease activity with age in their patient group.
Raised concentrations of autoantibodies to ANX5, ANX1, and ANX11 in rheumatoid arthritis may reflect damage to collagen containing tissues such as synovial joints. The consequences for inflammatory responses involving secretory phospholipase A2, collagen metabolism, and antibody regulation would be expected to be detrimental, but assessment will require a better understanding of the physiological role of annexins. The identification of annexin V as an autoantigen in rheumatoid arthritis expands the scope of autoimmune processes in this disease and may ultimately lead to the development of techniques for controlling them.
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